Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Mucopolysaccharidosis Type IVA

Metabolic & Lysosomal

Mucopolysaccharidosis Type IVA Clinical Trials

Also called MPS IVA, Morquio Syndrome Type A, Morquio A

Mucopolysaccharidosis Type IVA is caused by mutations in the GALNS gene, leading to deficiency of the enzyme N-acetylgalactosamine-6-sulfatase. Without this enzyme, the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate accumulate in lysosomes throughout the body, particularly in cartilage and bone. This accumulation disrupts normal skeletal development and causes progressive damage to connective tissues, heart valves, corneas, and the respiratory system.

In plain words, mucopolysaccharidosis type IVA is a condition where the body lacks an enzyme that breaks down certain sugar chains, so they build up. The buildup mainly harms bones and cartilage, causing short height and joint problems, while thinking is usually normal.

Get an email when new Mucopolysaccharidosis Type IVA trials open or the FDA decides. Get alerts

Mucopolysaccharidosis Type IVA

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 2 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Vimizim

Mucopolysaccharidosis Type IVA has 1 FDA-approved medicine, 3 open or active clinical trials (3 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Mucopolysaccharidosis Type IVA

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Mucopolysaccharidosis Type IVA

The skeletal features of Morquio A are distinctive: short trunk with a barrel-shaped chest, knock knees, spinal curvature, and joint laxity that together cause significant mobility challenges. Cervical spine instability from odontoid hypoplasia is a serious complication that can lead to spinal cord compression and paralysis. Respiratory function declines as the ribcage deformity restricts lung expansion.

Keep reading about Mucopolysaccharidosis Type IVA

Heart valve disease, corneal clouding, and hearing loss add to the disease burden. The FDA approved Vimizim (elosulfase alfa), an enzyme replacement therapy by BioMarin, on February 14, 2014 as the first treatment for MPS IVA. It is given into a vein once a week at 2mg per kg of body weight, over at least 3.5 to 4.5 hours.

In its main trial, people on Vimizim walked 22.5 meters farther in 6 minutes than people on placebo after 24 weeks, and it lowered keratan sulfate in urine. The label has a boxed warning for severe allergic reactions, including anaphylaxis, and says people with a breathing illness at the time of infusion may have serious breathing problems and need extra monitoring.

What are the symptoms of Mucopolysaccharidosis Type IVA?

These are common symptoms of Mucopolysaccharidosis Type IVA, and how strong they are varies from person to person.

  • Short stature and growth restriction beginning in early childhood
  • Kyphoscoliosis and progressive spinal curvature
  • Knock-knee deformity (genu valgum) causing difficulty walking
  • Barrel chest (pectus carinatum) and rib flaring
  • Progressive joint pain, stiffness, and laxity
  • Corneal clouding and progressive vision impairment
  • Hearing loss that worsens over time
  • Heart valve thickening and regurgitation
  • Obstructive sleep apnea and respiratory compromise
  • Dental abnormalities including thin enamel and widely spaced teeth

Who gets Mucopolysaccharidosis Type IVA?

The severe form typically appears between ages 1 and 3 with skeletal abnormalities becoming obvious as the child grows. A milder, slowly progressive form can appear in late childhood or adolescence. Affects males and females equally.

Autosomal recessive inheritance requiring mutations in both copies of the GALNS gene on chromosome 16. Intelligence is normal, though spinal cord compression from skeletal changes can cause neurological complications.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Mucopolysaccharidosis Type IVA?

There is currently 1 FDA-approved medication for Mucopolysaccharidosis Type IVA.

elosulfase alfa
BioMarin Pharmaceutical Inc.
Official site

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Mucopolysaccharidosis Type IVA treatment

Charity funds and drugmaker programs for Mucopolysaccharidosis Type IVA, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · National MPS Society
    Family Assistance Program fund
    Apply directly

    Pays for: Specialized equipment and medical aids not covered by insurance (requires insurance denial and 10% family copay), up to $3,000 per year.

    The foundation says: “Status not shown on page”
  • From a charity · National MPS Society
    Medical Travel Assistance Program fund
    Apply directly

    Pays for: Travel to out-of-town medical appointments more than 125 miles away (per year), up to $550 per year.

    The foundation says: “Status not shown on page”
  • From a charity · National MPS Society
    Journey Assistance Program fund
    Apply directly

    Pays for: Items that ease daily life (40% of purchase price), up to $500 per year.

    The foundation says: “Status not shown on page”
  • From a charity · NORD RareCare
    Morquio A Syndrome Medical Assistance fund
    Waitlist

    Pays for: Medical and medication costs.

    The foundation says: “Temporarily Waitlisting”
  • From a charity · NORD RareCare
    Morquio A Syndrome Premium Copay Assistance fund
    Waitlist

    Pays for: Insurance premiums and copays.

    The foundation says: “Temporarily Waitlisting”
Status as each foundation showed it on November 16, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Mucopolysaccharidosis Type IVA, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Mucopolysaccharidosis Type IVA

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Mucopolysaccharidosis Type IVA resources

Reputable organizations and medical references for learning more about Mucopolysaccharidosis Type IVA, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Mucopolysaccharidosis Type IVA

Use this Mucopolysaccharidosis Type IVA clinical trial finder to see the 3 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. Of these, 1 tests a treatment and 2 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

3 active trials worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenRecently updatedNCT07361536

Cardiac Structure and Function in MPS

Sponsor: Children's Hospital of Orange County

The purpose of this study is to better understand how heart and blood vessel problems develop in people with Mucopolysaccharidosis (MPS). The investigators are looking at certain substances in the body called GAGs and proteoglycans to see how they affect the heart. The investigat...

Ages 0 Years to 99 Years3 locations
Started Sep 2025Updated 1 month agoEst. Apr 2030 (~3y 5m)
RecruitingObservational study, no treatment givenNo updates in a whileNCT05284006

Non-invasive Functional Assessment and Pathogenesis of Morquio A

Intervention: Imaging, gait analysis, growth, joint test, hearing test, questionnaire, etc.

Sponsor: Nemours Children's Clinic

Morquio A disease is a devastating systemic skeletal disease in which detailed progression and pathogenesis remain unknown. The proposed project aims to establish a non-invasive objective assessment that can be applicable to all ages of patients to better understand the progress ...

Ages not specified1 location
Started May 2021Updated 6 months agoEst. Apr 2027 (~5 months)
RecruitingTreatment trialPhase 1No updates in a whileNCT04532047

PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)

Intervention: Aldurazyme (laronidase)

Sponsor: University of California, San Francisco

For detailed information, please view our study website: https://pearltrial.ucsf.edu/

The investigators aims to determine the the maternal and fetal safety and feasibility of in utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.

Ages 18 Years to 50 Years1 location
Started Jul 2021Updated 8 months agoEst. Jul 2031 (~4y 8m)
Find Mucopolysaccharidosis Type IVA trials near you, ranked by distance →
Active trial locations5 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

May 2021 to Nov 2031
2022
2024
2026
2028
2030
now
Phase 1
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Mucopolysaccharidosis Type IVA trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Mucopolysaccharidosis Type IVA foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Mucopolysaccharidosis Type IVA patient communities

Facebook groups, Reddit communities and YouTube channels where Mucopolysaccharidosis Type IVA patients, caregivers and advocacy groups talk.

Companies developing Mucopolysaccharidosis Type IVA treatments

Drugmakers that list Mucopolysaccharidosis Type IVA in their rare disease portfolio, 1 in all.

Questions people ask about Mucopolysaccharidosis Type IVA